HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development

Glycolytic reprogramming is a typical feature of many cancers; however, key regulators of glucose metabolism reengineering are poorly understood, especially in cutaneous squamous cell carcinoma (cSCC). Here, Homeobox A9 (HOXA9), a direct target of onco-miR-365, is identified to be significantly down...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Liang, Wang, Yinghui, Zhou, Meijuan, Zhang, Ying, Wang, Pengfei, Li, Xiaoxing, Yang, Jing, Wang, Hongmei, Ding, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902613/
https://www.ncbi.nlm.nih.gov/pubmed/29662084
http://dx.doi.org/10.1038/s41467-018-03914-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902613/
https://www.ncbi.nlm.nih.gov/pubmed/29662084
http://dx.doi.org/10.1038/s41467-018-03914-5

Ejemplares similares